NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q2 2026 Earnings Call Transcript May 12, 2026

NeuroOne Medical Technologies Corporation misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.22667.

Operator: Good day, ladies and gentlemen, and welcome to NeuroOne Medical Technologies Corporation’s Second Quarter Fiscal 2026 Financial Results Conference Call. Today’s call will be conducted by the company’s Chief Executive Officer, Dave Rosa; and Ron McClurg, the company’s Chief Financial Officer. Before I turn the call over to Mr. Rosa, I’d like to remind you that this conference call will include forward-looking statements within the meaning of U.S. federal securities laws with respect to future operations, financial results, including events, trends and performance, which are based on management’s beliefs and assumptions as of today’s call. Forward-looking statements may involve known and unknown risks, uncertainties and other factors, which may cause results — actual results to differ materially from those expressed or implied by such statements.

See NeuroOne’s financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NeuroOne undertakes no obligation to update such forward-looking statements. With that, I will turn the call over to Mr. Dave Rosa, Chief Executive Officer of NeuroOne. Please go ahead, sir.

David Rosa: Thank you, operator, and thank you to everyone for joining us today. I’d like to welcome you to our second quarter fiscal 2026 financial results conference call. Product revenue for the OneRF brain ablation system in the second quarter of fiscal 2026 grew 72% year-over-year to $2.4 million compared to $1.4 million in the second quarter of fiscal 2025. We continue to be energized by reports of the positive impact this therapy is having on people’s lives. Most recently, the U.S. Department of Veterans Affairs published an article regarding Dr. Garrett Banks experience with the technology. The article discussed the challenges that Navy veteran Derek Harpole had to endure after being diagnosed with epilepsy. For more than 2 decades, he was unable to work, drive or hunt alone.

Dr. Banks and his team at the Houston VA performed their first OneRF brain ablation procedure on Derek. He woke up the morning after the procedure bright-eyed and bushy-tailed in his words. With his seizures dramatically reduced, he now has hope that he can regain the life he once had. Through our partnership with Zimmer Biomet, our goal is to expand this therapy into new centers in order to change other people’s lives as well. The company also had several important corporate developments I’d like to highlight. First, we appointed David Wambeke as Chief Business Officer to lead our drug delivery program, oversee Investor Relations and support business development. As a meaningful sign of his confidence, David purchased 1 million shares of NeuroOne common stock on a pre-split basis.

We were also pleased to announce that we regained compliance with NASDAQ’s minimum bid price requirement following a 1-for-6 reverse split of our common stock. Finally, we are always excited to welcome new investors, and we’re pleased to learn a new high net worth investor acquired approximately 7.4% of our outstanding common stock in the open market. Now let’s move on to discuss the exciting progress we have made with our existing product portfolio. Regarding our OneRF brain ablation system, as I mentioned in the opening, we experienced 72% year-over-year revenue growth. We believe there is upside for growth domestically and internationally. Domestically, we are developing a webinar that will highlight clinical experience with the device that we can expand exposure to neurologists and neurosurgeons that may not be aware of the exciting results that are being reported.

With respect to international commercialization progress, we completed the Stage 2 audit of our Minnesota facility for ISO 13485 certification and remain bullish on certification in the latter part of 2026, which is a key step in the process of enabling international distribution of our products. We also had an important clinical milestone this quarter with the publication of a peer-reviewed case series that validates what physicians using our platform have been telling us. That real-time temperature monitoring during SEEG-guided RF ablation is an important technology feature when performing brain ablations on patients with drug-resistant epilepsy. The OneRF brain ablation system was also highlighted at Zimmer Biomet’s booth at the American Association of Neurological Surgeons meeting in San Antonio, Texas, alongside presentations on the technology.

Moving on to our OneRF trigeminal nerve ablation system. We have continued to gain clinical experience and have experienced clinical success following our FDA 510(k) clearance and limited market release. To date, we have successfully completed 16 cases using the ablation system for the treatment of facial pain known as trigeminal neuralgia, with all patients reportedly pain-free after the procedure. We continue to be optimistic regarding the advantages and clinical performance of the device for treating facial pain. As a reminder, unlike traditional ablation systems, our product is intended to be placed once due to the multiple contacts present on the device, whereas traditional systems typically require multiple probe placements that can cause additional patient discomfort and extend treatment times.

We were also pleased to be highlighted in the Business Research Company’s April 24, 2026 report, which noted that emerging growth patterns are driving expansion in the trigeminal neuralgia market valued at approximately $780 million toward stereotactic surgery using technology similar to our OneRF trigeminal nerve ablation system. Regarding our drug delivery program, we remain on track for commercial availability of the system in the second half of fiscal 2026 for use in investigational clinical studies or animal studies. Also, we are currently evaluating distributors for commercialization of the product. In addition, we announced a collaboration with the Department of Neurology’s Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating next-generation epilepsy therapies using our drug delivery platform.

Moving on to our two lower back pain management programs. I will first provide an update on our Basivertebral nerve ablation system. This quarter, we completed the user design requirements for the system and initiated preclinical testing to support continued development of the program. Our strategy remains to leverage our existing OneRF generator, temperature accessory and ablation electrode while outsourcing access tools either through outside vendors or potential distribution partners. We continue to remain excited about the prospects of the system given the potential clinical advantages it offers. Now let’s move on to our spinal cord stimulation percutaneous paddle lead program. As a reminder, this system is designed to offer broader customizable stimulation, lower energy consumption and can be inserted through a 14-gauge needle, eliminating the need for an incision in the patient’s back.

During the quarter, we concluded our chronic animal study and identified opportunities to enhance performance. In addition, the system was also displayed at the North American Neuromodulation Society or otherwise known as NANS, and we received a great deal of interest from physicians that stopped by our booth. Finally, we also announced a CFO transition plan. Ron McClurg, who has served as our CFO with great distinction for over 5 years, will retire as CFO effective June 30, 2026, and remain a senior adviser to the company through year-end. Effective July 1, 2026, Chris Volker, our current Chief Operating Officer, will assume the role of Chief Financial Officer. We are confident that this transition will be seamless and support continued execution against our strategic priorities.

I also want to personally thank Ron for all his efforts, his commitment and his willingness to remain through this transition, and I am confident that Chris Volker is a great fit for this role. I would now like to turn the call over to Ron to provide a review of our second quarter fiscal 2026 financial results.

Ronald McClurg: Thanks, Dave. Product revenue was $2.4 million in the second quarter of fiscal 2026, a 72% increase compared to product revenue of $1.4 million in the second quarter of fiscal 2025. The increase was driven by higher sales of OneRF products. For the 6 months ended March 31, 2026, Product revenue was $5.3 million, an increase of 13% compared to $4.7 million in the same period of the prior fiscal year. The company had no license revenue in the second quarter or first 6 months of fiscal 2026 compared to license revenue of $3 million in the first 6 months of fiscal 2025, which was derived from the expanded exclusive distribution agreement with Zimmer Biomet. Product gross profit was $1.3 million or 53.8% of product revenue in the second quarter of fiscal 2026 compared to product gross profit of $0.8 million or 55.6% of product revenue in the same quarter of the prior fiscal year.

For the 6 months ended March 31, 2026, product gross profit was $2.9 million or 54.0% of product revenue compared to $2.7 million or 57.9% of product revenue in the same period of the prior fiscal year. Total operating expenses were $3.4 million in the second quarter of fiscal 2026 compared to $3.5 million in the same quarter of the prior year. Research and development or R&D expense in the second quarter of fiscal 2026 was $1.5 million compared to $1.5 million in the same quarter of the prior year. Selling, general and administrative or SG&A expense in the second quarter of fiscal 2026 was $1.9 million compared to $1.9 million in the same quarter of the prior year. For the first 6 months of fiscal 2026, total operating expenses were $6.7 million compared to $6.7 million in the same period of fiscal 2025.

R&D expense in the first 6 months of fiscal 2026 was $2.9 million compared to $2.7 million in the same period of fiscal 2025. SG&A expense in the first 6 months of fiscal 2026 decreased 4% to $3.8 million compared to $4.0 million in the prior year period. Net loss in the second quarter of fiscal 2026 was $2.1 million or $0.25 per basic and diluted share compared to a net loss of $2.3 million or $0.44 per basic and diluted share in the same quarter of the prior year. The net loss in the second quarter of fiscal 2025 was favorably impacted by a $0.4 million gain from the fair value change in the warrant liability. For the 6 months ended March 31, 2026, net loss was $3.5 million or $0.42 per basic share and $0.44 per diluted share compared to a net loss of $0.5 million or $0.09 per basic and diluted share in the same period of the prior year.

The lower net loss in the first 6 months of fiscal 2025 reflected a $3 million of license revenue recognized in the first quarter of fiscal 2025. As of March 31, 2026, the company had cash and cash equivalents of $2.8 million compared to $6.6 million as of September 30, 2025. The company also had $2.4 million in accounts receivable as of March 31, 2026, which should be converted to cash in the third quarter of fiscal 2026 based on normal collection patterns. The company had working capital of $5.7 million as of March 31, 2026, compared to working capital of $7.9 million as of September 30, 2025. NeuroOne had no debt outstanding as of March 31, 2026. Before I turn the call back to Dave for his closing remarks, I would like to thank Dave and the Board of Directors for giving me the opportunity to be part of such a talented team.

It has been a privilege to serve as NeuroOne’s Chief Financial Officer for over 5 years and to see the life-changing results our products are providing for patients. I look forward to watching the continued growth and success of NeuroOne.

David Rosa: Thank you, Ron. In summary, this was a very productive quarter for the company. We delivered 72% year-over-year product revenue growth, gained meaningful clinical experience with our OneRF trigeminal nerve ablation system, completed the Stage 2 ISO 13485 audit, paving the way for international distribution, regained NASDAQ compliance and added two highly experienced executives and Dave Wambeke as Chief Business Officer; and effective July 1, Christopher Volker as our next Chief Financial Officer. Looking ahead, the catalysts are clear: continued commercial expansion of the OneRF brain ablation and OneRF trigeminal neuralgia ablation systems, commercial availability of our drug delivery system later this year, continued progress in our back pain technologies and future international commercial expansion.

I am proud of what our team has built and believe we remain well positioned for the future. Finally, I look forward to sharing more of our story with investors at the Planet MicroCap Conference in Las Vegas in June. With that, operator, at this time, we can open up the call for questions.

Q&A Session

Operator: [Operator Instructions] Our first question is coming from Jeff Cohen with Ladenburg Thalmann.

Destiny Buch: This is Destiny on for Jeff. Can we start with the drug delivery timing and strategy? I know you mentioned that it would be available for partnering and clinical evaluation in the second half of ’26. So I’m curious what’s left on your end to do? And this is — I think this is the first time I’ve heard you mention working with a distributor. Can you just walk us through that and that strategy a bit?

David Rosa: Sure. And thanks for joining the call, Destiny. So really, what’s left is for us to finish our sterilization testing and validation in packaging. Once that’s done, and it usually takes about 3 months, we’ll be in a position to start shipping the product. And again, it’s for any animal use as well as any approved human IDE studies. And we obviously don’t have a direct sales force today. So the best way, we think, of really being able to commercialize the technology, at least initially for animal use is to identify the distributors that sell into those areas. So that’s the plan there. And yes, I think you probably also heard that we just partnered with the University of Minnesota regarding some of the therapies that they would like to test. They’re not the only health care system that’s approached us. We expect to have more of those as well in the future.

Destiny Buch: Okay. Got it. And then turning to face pain for a second. I’m wondering how that commercialization strategy has changed or evolved as you’re getting more of these procedures done. And then I wanted to follow up on one of my questions from — I think it was December about scheduling. Are you seeing the same trends? I know you only had a couple when I asked the question originally, but are you seeing consistent trends with these physicians performing multiple ablations in different patients a day? Or has that kind of changed?

David Rosa: I’ll answer the second question first. No, that’s remained, and I expect that it will continue to be that way. It’s a lot easier to really schedule these cases than it is the brain ablation cases because there’s always the waiting period on the brain ablation cases to identify the focal area. Here, when the patient comes in, they know they’re getting an ablation. So the neurosurgeons at the sites that we’re at are stacking these cases in a day, and that makes it really easy to plan for that. The commercialization strategy really hasn’t changed. I still expect that we’ll be partnering with another company. But until any agreement is final, we’ll continue to do what we’re doing, which is really opening up centers ourselves.

Destiny Buch: Got it. Okay. And then lastly, I just wanted to ask on guidance. I know you gave a top line of, I think it’s 10.5% for product revenue for 2026. I’m wondering if that outlook kind of remains the same. And I know it did not include anything for drug delivery or facial pain. So I’m wondering if you can give us any updates there?

David Rosa: It still remains the same, the guidance. And you’re correct. It doesn’t include anything from those areas. I think by the time we get to commercialize drug delivery, it will be late in our fiscal year. So I’m not expecting any major contributions from that area. And in terms of facial pain, it also really depends on how quickly we’re able to finalize an agreement.

Operator: Our next question is coming from Jeremy Pearlman with Maxim Group. _p id=”613074829″ name=”Jeremy Pearlman” type=”A” /> Firstly, I wanted to speak a little bit about the international opportunity. You hope to get certification by the end of ’26. Is that going to be — is that commercial rollout going to be with Zimmer? Is that — or is that potentially there with Zimmer? Or is it going to be through other distributors? And also maybe are there countries that you’ve targeted to be the first ones for that launch? Or maybe any update on that would be great?

David Rosa: Yes. Thanks for joining the call as well. So yes, the initial plan will be to enter international markets with Zimmer. In our agreement with Zimmer, they actually have certain geographies as part of the agreement, but there are some additional geographies that they don’t have distribution rights to. So there is a chance that we will partner with other distributors for geographies that Zimmer has not signed up for. In terms of where we’re going to focus on first, that’s really in process right now with the Zimmer folks. The good news is that they’re more than willing to help us help support any registrations or regulatory clearances that we need. But we are waiting to come up with a final list of at least the initial territories that we’re looking to target. We would like to go to those geographies that accept FDA clearance so that there aren’t any additional requirements for the company. But I expect next quarter to have more information on that.

Jeremy Pearlman: Okay. Great. And then maybe, again, these are some KPIs. I don’t know if you have all this information because I know it’s sold a lot of it through Zimmer. Can you quantify how many procedures this quarter were performed by VP physicians versus, let’s say, first-time users, so we can get some sense of how it’s trending both within the current installed base and then potentially new users?

David Rosa: Yes, we don’t have that information from Zimmer.

Jeremy Pearlman: Okay. Understood. And I mean — and then jumping to the trigeminal, — is there — could you remind us, I’m not sure if this information might have slipped my head. Is there a CPT code that covers that procedure? Or is it being billed under an existing CPT code? Maybe how should we look at the reimbursement landscape for the trigeminal ablation device?

David Rosa: Yes. It is being built under an existing code. I don’t — in terms of what the code number is, I don’t know that off the top of my head.

Operator: Our next question is coming from Justin Walsh with JonesTrading.

Unknown Analyst: This is Bill on for Justin Walsh at Jones. We are curious on how are you driving new physician adoption for your OneRF system for facial pain.

David Rosa: I’m sorry, could you repeat the question? I just couldn’t hear very clearly. p id=”A00″ name=”Unknown Analyst” type=”A” /> How are you driving new physician adoption for your OneRF system for facial pain?

David Rosa: Sure. So we’re targeting centers that already have a generator at their facility. And if you remember, the surgeons that are performing the facial pain procedures are the same ones that are performing the brain ablation procedures. And I think if you look at the results to date, what we’ve said publicly is that 16 cases that we’ve currently done, all are pain-free. So I think being able to really broadcast that data as we go to new sites that the system, in addition to seeing that so far, patients are pain-free, it also is a much more comfortable procedure for the patient because our device only has to be placed a single time as opposed to other existing technologies where the probe has to be placed multiple times until the neurosurgeon has found the area of the nerve that’s triggering pain.

Because we have multiple contacts on the electrode, we can place it once and then test each of those contacts. So in other words, the patient doesn’t have to get that probe placed multiple times. So that typically leads to shorter procedures and certainly a higher level of comfort. And the surgeons so far that we’ve gone to understand that and can appreciate it. So I don’t think it’s going to be that difficult to continue to show the advantages of our system.

Unknown Analyst: Okay. And would you please expand on your time line for your spinal cord stimulation percutaneous paddle program?

David Rosa: I’m sorry, again, I’m having a little trouble hearing. Could you repeat that?

Unknown Analyst: Yes, of course. Would you expand on your time line for your spinal cord stimulation percutaneous paddle program? What’s the time line for that program?

David Rosa: Yes. So we haven’t put out a time line yet. And now with some of the adjustments that we want to make, we’ll have to figure out what that time line is going to look like. But at this point, we’re still trying to investigate the steps for what we want to do to make some enhancements on the system. So that will be something that we’ll likely provide, I would assume, in the next 1 to 2 quarters.

Operator: That appears to be the last question at this time. So I would like to turn the call back over to Mr. Dave Rosa for any closing remarks.

David Rosa: Thank you, operator. I would like to thank everyone again for attending the call and look forward to connecting with the investor community throughout the quarter. If we were unable to answer any of your questions today, please reach out to our IR firm, MZ Group, who would be more than happy to assist.

Operator: Thank you. Ladies and gentlemen, this concludes today’s conference. We thank you for your participation, and you may disconnect your lines at this time, and we hope you have a great day.